The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and effectiveness of Fruquintinib combined
with Albumin Paclitaxel and Gemcitabine on pancreatic cancer patients with liver metastases.
Plan to enrollment 30 patients.